TGFB1 and neoplasm: Changes in CTC numbers during Atezo+Bev treatment reflected the tumor volume, and patients with elevated transforming growth factor (TGF)-β signaling molecules had a poorer response, whereas those with elevated apoptosis signaling molecules had a favorable response.